JBR-102
Glioblastoma Multiforme (GBM), Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma, Hematologic Malignancy
PreclinicalActive
Key Facts
Indication
Glioblastoma Multiforme (GBM), Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma, Hematologic Malignancy
Phase
Preclinical
Status
Active
Company
About Jupiter BioMedical Research
Jupiter Biomedical Research is a preclinical-stage biotech focused on developing novel small molecule therapeutics for oncology and virology. Its lead asset, JBR-102, is being developed as an oral formulation for glioblastoma and other solid and hematologic tumors, while JBR-201 is an antiviral candidate with potential activity against a broad spectrum of viruses. The company appears to be a private, pre-revenue entity with a management team listed on its website but no disclosed clinical data, investors, or partners, indicating an early-stage venture seeking to advance its candidates into clinical development.
View full company profile